The Current Standard-of-Care for Patients with HER2+ Metastatic Breast Cancer
October 6th 2022Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.
Read More
Patient Profile 1: Sequencing Therapies in HER2+ mBC
April 15th 2022Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
Read More